Skip to main content

The Biomarker Company

SphingoTec develops and markets innovative in vitro diagnostics solutions for novel and proprietary blood-based protein biomarkers. Our aspiration is to effectively translate scientific advancements into routine clinical practice.

Our innovative biomarkers address diagnostically underserved critical care conditions such as sepsis, acute heart failure, acute kidney injury, and cardiogenic shock. 
We are a fully integrated diagnostics company: our innovative biomarkers are commercially available on the point of care platform Nexus IB10. The assay portfolio for near patient testing goes beyond innovation: on the Nexus IB10 platform, clinicians can deploy a wide range of commonly used parameters in acute and critical care settings, making the analyzer a useful addition to intensive care units (ICU), emergency departments (ED), and other near patient settings. 

Integrated diagnostic solutions for unmet medical needs

Rapid Testing

Point of care diagnostics

Nexus IB10 is a point of care analyzer that provides rapid and reliable diagnostic results. Fully automatic and compact, Nexus IB10 is a solution for near patient testing in acute and critical care settings. 

Test portfolio

Biomarker-based diagnostics

The Nexus IB10 test portfolio includes biomarker innovations and established parameters for acute and critical care such as PCT, Troponin, NT-proBNP, D-dimer, TSH, and others. 

From bench to bedside

Biomarker innovations

The main mortality drivers in intensive care units are diagnostic blind spots. We pave the way for early intervention and personalized medicine in critical care with innovative biomarkers.


Latest News

08. August 2022
International medical experts discussed the latest developments in diagnostic and therapeutic innovations for advancing precision medicine in critically ill patients during the 4th Scientific Symposium.
Read more
01. August 2022
New findings support the clinical value of the biomarker bio-ADM for triaging sepsis patients in ED, exceeding the prognostic performance of routine biomarkers. So far, the predictive potential of the innovative biomarker has been confirmed and used primarily in ICU. A new study, recently published, confirms its applicability in ED.
Read more
30. June 2022
Jörg Menten, previously acting as Chief Commercial Officer of the company, will focus on successfully commercializing the biomarker-based diagnostics that address high unmet needs in critical care settings. Dr. Andreas Bergmann assumes the role of CSO within SphingoTec to further develop strategic innovations.
Read more

Events & Expos

21. - 24. March 2023

08:05 - 10:07

Brussels, Belgium

The International Symposium on Intensive Care and Emergency Medicine is organized by the Departments of Intensive Care and Emergency Medicine of Erasme University Hospital, Université Libre de…

Read more
15. - 17. February 2023

08:02 - 10:03

Bremen, Germany

The Symposium Intensivmedizin + Intensivpflege in Bremen is the largest annual meeting of intensive care physicians and nurses, administrative experts, and industry representatives independent of…

Read more
30. November - 02. December 2022

13:08 - 15:10

Hamburg, Germany
The DIVI is the largest event for emergency and intensive care medicine in German-speaking countries. We look forward to once again be exhibiting.
Read more

Subscribe to our Newsletter

Follow the link below to subscribe to our Newsletter & receive updates on our company and products

Subscribe now

Follow our Journey on Social Media